NO20100685L - Polypeptid samt anvendelse derav og peptidkompleks, og fremgangsmate for identifisering av et organisk eller uorganisk molekyl - Google Patents

Polypeptid samt anvendelse derav og peptidkompleks, og fremgangsmate for identifisering av et organisk eller uorganisk molekyl

Info

Publication number
NO20100685L
NO20100685L NO20100685A NO20100685A NO20100685L NO 20100685 L NO20100685 L NO 20100685L NO 20100685 A NO20100685 A NO 20100685A NO 20100685 A NO20100685 A NO 20100685A NO 20100685 L NO20100685 L NO 20100685L
Authority
NO
Norway
Prior art keywords
protein
proteins
encode
organic
binding site
Prior art date
Application number
NO20100685A
Other languages
English (en)
Inventor
Jan Zavada
Silvia Pastorekova
Jaromir Pastorek
Original Assignee
Inst Of Virology Slovak Academ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/178,115 external-priority patent/US6297041B1/en
Priority claimed from PCT/US1999/024879 external-priority patent/WO2000024913A2/en
Publication of NO20100685L publication Critical patent/NO20100685L/no
Application filed by Inst Of Virology Slovak Academ filed Critical Inst Of Virology Slovak Academ

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Lokaliseringen av MN-protein-bindingssetet og MN-proteiner/polypepider som konkurrerer om tilkobling til vertebratceller med immobilisert MN-protein, beskrives. Slike MN- proteiner/polypeptider forhindrer celle-celle-adhesjon og dannelsen av intercellulære kontakter. MN-protein-bindingssetet er et terapeutisk mål som kan blokkeres av organiske eller uorganiske molekyler, fortrinnsvis organiske molekyler, mer foretrukket proteiner/polypeptider, som spesifikt binder til dette setet. Terapeutiske metoder for inhibering av veksten av preneoplastiske/neoplastiske vertebratceller som unormalt uttrykker MN-protein, er omtalt. Det tilveiebringes vektorer som koder for de variable domener av MN-spesifikke antistoffer og et fleksibelt linker-polypeptid som adskiller disse domenene. Dessuten beskrives ytterligere vektorer som koder for et cytotoksisk protein/polypeptid operativt koblet til MN-genpromoteren og som fortrinnsvis ytterligere koder for et cytokin. MN-genpromoteren er karakterisert, og bindingssetet for en repressor av MN-transkripsjon er beskrevet.
NO20100685A 1998-10-23 2010-05-12 Polypeptid samt anvendelse derav og peptidkompleks, og fremgangsmate for identifisering av et organisk eller uorganisk molekyl NO20100685L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/178,115 US6297041B1 (en) 1992-03-11 1998-10-23 MN gene and protein
US09/177,776 US6297051B1 (en) 1997-01-24 1998-10-23 MN gene and protein
PCT/US1999/024879 WO2000024913A2 (en) 1998-10-23 1999-10-22 Mn gene and protein

Publications (1)

Publication Number Publication Date
NO20100685L true NO20100685L (no) 2001-06-19

Family

ID=25142394

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20100685A NO20100685L (no) 1998-10-23 2010-05-12 Polypeptid samt anvendelse derav og peptidkompleks, og fremgangsmate for identifisering av et organisk eller uorganisk molekyl

Country Status (5)

Country Link
US (1) US6297051B1 (no)
JP (1) JP5021717B2 (no)
CA (1) CA2763066A1 (no)
NO (1) NO20100685L (no)
PT (1) PT1123387E (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713704B1 (en) * 1998-10-23 2010-05-11 Institute Of Virology Of The Slovak Academy Of Science MN gene and protein
US6379907B1 (en) 1999-08-05 2002-04-30 The Regents Of The University Of California Diagnostic method using expression of MN/CA9 protein in AGUS Pap smears
US6403327B1 (en) 1999-08-05 2002-06-11 The Regents Of The University Of California Diagnostic method using expression of MN/CA9 protein in ASCUS Pap smears
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
AR036833A1 (es) * 2001-10-18 2004-10-06 Bayer Corp Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
US20060084123A1 (en) * 2001-12-13 2006-04-20 Harris Adrian L MN and hypoxia
HUE026218T2 (en) * 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
SI2508596T1 (sl) 2002-02-21 2016-01-29 Institute Of Virology Slovak Academy Of Sciences Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
DE60328477D1 (de) * 2002-04-16 2009-09-03 Univ California Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
US20090239247A1 (en) * 2002-12-13 2009-09-24 Harris Adrian L MN and Hypoxia
US20050075543A1 (en) * 2003-10-03 2005-04-07 Calabrese Charles A. Method of anonymous medical testing and providing the patient with the test results
US20100056611A1 (en) 2006-10-12 2010-03-04 Jaromir Pastorek MN/CA9 Splice Variants
US20100317533A1 (en) * 2009-06-05 2010-12-16 British Columbia Cancer Agency Branch Biomarkers of cancer metastasis
EP4019552A1 (en) 2015-06-10 2022-06-29 National Research Council of Canada Carbonic anhydrase ix-specific antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5387676A (en) 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
AU2861695A (en) 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein

Also Published As

Publication number Publication date
JP2010088443A (ja) 2010-04-22
US6297051B1 (en) 2001-10-02
CA2763066A1 (en) 2000-05-04
JP5021717B2 (ja) 2012-09-12
PT1123387E (pt) 2008-01-29

Similar Documents

Publication Publication Date Title
NO20100685L (no) Polypeptid samt anvendelse derav og peptidkompleks, og fremgangsmate for identifisering av et organisk eller uorganisk molekyl
CY1107268T1 (el) Μν γονιδιο και πρωτεϊνη
WO1999055868A3 (en) Fizz proteins
DE69840600D1 (de) Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t-zellen
CA2804256C (en) Bacterial surface display and screening of thioether-bridge-containing peptides
CA2497496A1 (en) In vitro peptide expression library
NO20020861D0 (no) PD-1, en reseptor for B7-4, og anvendelser derav
Lee et al. Glutamine (Q)‐peptide screening for transglutaminase reaction using mRNA display
NO962991D0 (no) Zink-finger-proteinderivater og fremgangsmåter
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
AU1860395A (en) Novel human beta 2 integrin alpha subunit
DE69827810D1 (de) Methode zum durchforsten von banken mittels chimären bindungspetiden
Petersen et al. Synthesis of tumor necrosis factor α for use as a mirror-image phage display target
DE69435020D1 (en) Protein-tyrosin-phosphatase ptp-s31
KR870001311A (ko) 단백질 및 폴리펩티드의 제조 방법
KR850006550A (ko) 단백질의 제조방법
ATE315787T1 (de) Methoden zur identifizierung von modulatoren wechselwirkender proteine
WO2002005843A3 (en) Human rrp sequences and methods of use
ATE321854T1 (de) Hypophysentumor verursachende gene und verwandte produkte
SE0003573D0 (sv) Method and means for producing novel von Willebrand factor binding proteins and their use in biotechnology
ES2152976T3 (es) Proteina crp mutante, procedimientos y medios para su fabricacion y su utilizacion.
DK1233980T3 (da) Nukleinsyremolekyle, omfattende en nukleinsyresekvens, der koder for et hæmocyanin, og mindst en intronsekvens
WO2023047376A2 (en) Peptide constructs for targeted protein degradation
Hexham et al. Optimization of the anti‐(human CD3) immunotoxin DT389–scFv (UCHT1) N‐terminal sequence to yield a homogeneous protein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application